{{cart_num}}
My Cart> Molecular Biology > Recombinant Clone Expression > Competent Cell > BL21(DE3)pLysS Competent CellsStorage：Store in liquid nitrogen，1 year;Store at -70℃，6 months
Appearance：Dry ice transport, only 10kg dry ice fee
Qty：
Size：
| Name | BL21(DE3)pLysS Competent Cells |
| Appearance | Dry ice transport, only 10kg dry ice fee |
| Storage | Store in liquid nitrogen，1 year;Store at -70℃，6 months |
| Unit | Bag |
| Specification | 10*100ul 20*100ul |
BL21 (DE3) pLysS receptive cells produced by our company are receptive cells obtained by special processing of Escherichia coli BL21 (DE3) pLysS strain, which can be used for chemical transformation of DNA. Using pUC19 plasmid detection, the conversion efficiency can reach 107, and the conversion efficiency does not change after 6 months of storage at -70℃.
Genotypes: F-, ompT, hsdSB(rB-mB-), dcm, gal(DE3), pLysS, Cmr
Characteristics: This strain carries the plasmid pLysS and is therefore resistant to chloramphenicol. Plasmid pLysS contains genes expressing T7 lysozyme, which can reduce the background expression level of target genes, but does not interfere with the expression of target proteins. The bacterium is suitable for expressing both toxic and non-toxic proteins.
Note：Product information may be optimized and upgraded. Please refer to the actual label information for accuracy.
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no experimental images.
Sorry, there is no more information.
Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment
Click to check >>Author：Siyu He, Xianglin Chu, Yujia Wu, Jiheng Jiang, Pengfei Fang, Yuting Chen, Yang Liu, Zhixia Qiu, Yibei Xiao, Zhiyu Li, Di Pan, Qian Zhang, Huanfang Xie, Shuaishuai Xing, Feng Feng, Wenyuan Liu, Qinglong Guo, Li Zhao, Peng Yang, Haopeng Sun
IF：7.3000
Publish_to：JOURNAL OF MEDICINAL CHEMISTRY
PMID：37409679
